In vivo tumor efficacy: In the first in vivo experiment, nab-PTX was tested against NIC made with STI-3031 or atezolizumab, a clinically approved anti-PD-L1 antibody (Figure 4a). The gene discussed is CD274; the disease is neoplasm.